SCHEMBL12419782

SCHEMBL12419782

Cn1c2ccccc2c2cc3c(cc21)c1cc(-c2ccc4c(c2)c2cc5c(cc2n4C)c2ccccc2n5C)ccc1n3C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.64
KDM4E B2RXH2 4/20 0.58
HPGD P15428 4/20 0.58
MAPT P10636 3/20 0.58
ALDH1A1 P00352 3/20 0.58
L3MBTL1 Q9Y468 3/20 0.58
HSD17B10 Q99714 3/20 0.58
MEN1 O00255 1/20 0.58
HTT P42858 1/20 0.58
KMT2A Q03164 1/20 0.58
RXRA P19793 1/20 0.53
RXRB P28702 1/20 0.53
KIF11 P52732 1/20 0.51
PABPC1 P11940 1/20 0.51
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ATM Q13315 1/20 0.46
NPY5R Q15761 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12419786 0.98 GPR3 (0.61) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL12418695 0.98 GPR3 (0.61) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL10447275 0.96 GPR3 (0.70) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL10331500 0.96 GPR3 (0.70) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL10447279 0.94 GPR3 (0.61) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL17809439 0.94 GPR3 (0.67) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL12419781 0.92 GPR3 (0.64) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL16848587 0.92 GPR3 (0.64) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL13086784 0.92 GPR3 (0.64) GPR3KDM4EHPGDMAPTALDH1A1
SCHEMBL21524767 0.91 GPR3 (0.57) GPR3KDM4EHPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003807-B2 organic thin film transistor with a semiconductor layer including the small molecule having didodecylindolo[3,2-b]carbazole groups XEROX CORPORATION (US) 2011-08-23 US disclosed
US-7868186-B2 Device containing polymer having indolocarbazole- repeat unit and divalent linkage XEROX CORPORATION (US) 2011-01-11 US disclosed
US-7829727-B2 Device containing compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2010-11-09 US disclosed
US-20100230670-A1 DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2010-09-16 US disclosed
US-20090114909-A1 organic thin film transistor with a semiconductor layer including the polymer of 2,8-Bis(2-thienyl)-5,11-didodecylindolo[3,2-b]carbazole; organic photovoltaics XEROX CORPORATION (US) 2009-05-07 US disclosed
US-7528261-B2 Small molecule compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2009-05-05 US disclosed
US-20080207917-A1 POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2008-08-28 US disclosed
US-7402681-B2 Compound with indolocarbazole moieties and devices containing such compound XEROX CORPORATION (US) 2008-07-22 US disclosed
US-7396852-B2 Compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2008-07-08 US disclosed
US-20080103314-A1 SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2008-05-01 US disclosed
US-20070112167-A1 Device containing compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION 2007-05-17 US disclosed
US-20070112172-A1 Compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112172-A1 Compound having indolocarbazole moiety and divalent linkage INMT, IDO2, GRIN2C GPR3 1336/4885KDM4E 3375/4885HPGD 2880/4885
US-20080103314-A1 SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE SLC43A1, SLC7A5, KCNN2 GPR3 1530/4885KDM4E 4093/4885HPGD 3356/4885
US-20100230670-A1 DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE BRD4, BICRA, INMT GPR3 2016/4885KDM4E 3154/4885HPGD 2717/4885
US-20080207917-A1 POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE SGTA, MTCL3, SMC3 GPR3 2775/4885KDM4E 4060/4885HPGD 2811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.